PHYSIOLOGIC GH ADMIN ON CARDIOVASCULAR RISK MARKERS IN WOMEN WITH GH DEFICIENCY

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 回顾性研究显示，生长激素（GH）缺乏的成人心血管死亡率增加。 生长激素缺乏综合征与心血管风险标志物增加有关，生长激素管理已被证明对许多这些因素有有益的影响。这项为期12个月的研究的目的是评估生长激素替代治疗对18-65岁女性心血管风险标志物的影响，这些女性由于垂体/下丘脑疾病、放射或手术而缺乏生长激素。 在本研究的前6个月，受试者接受GH或安慰剂（一种非活性物质），所有受试者在研究的剩余6个月接受GH。 我们正在评估血液中的心血管风险标志物、身体成分、血管弹性、心率变异性和生活质量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cardiovascular mortality in growth hormone (GH) deficient adults has been shown to be increased in retrospective studies. GH deficiency syndrome is associated with increased cardiovascular risk markers, and GH administration has been shown to have beneficial effects on a number of these factors. The aim of this 12-month study is to evaluate the effects of GH replacement on cardiovascular risk markers in women, ages 18-65, who are GH deficient due to pituitary/hypothalamic disease, radiation, or surgery. For the first 6 months of this study, subjects receive either GH or placebo (an inactive substance), and all subjects receive GH for the remaining 6 months of the study. We are assessing cardiovascular risk markers in the blood, body composition, flexibility of blood vessels, heart rate variability and quality of life.